HepeX-B

Phase 2Small molecule

Merck & Co.

HepeX-B is one of 6 small molecule programs targeting End Stage Liver Disease. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

End Stage Liver DiseaseActive, not recruiting

End Stage Liver DiseasePhase 2

Active, not recruiting

Competition

Competitive Landscape

6 competitors in End Stage Liver Disease

#DrugCompanyPhaseTrials

Hepatitis B Immune Globulin

Merck & Co.

Phase 2

1 2

Myfortic

Novartis

Preclinical

—3

Raltegravir Potassium

Merck & Co.

Phase 2

1 4

Tocotrienol

FFondazione IRCCS Istituto Nazionale dei Tumori, Milano

Phase 2

1 5

HepeX-B

Merck & Co.

Phase 2

1 6

Antibiotics

MMelinta Therapeutics, Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

End Stage Liver Disease1 trial

HepeX-B in Post Hepatic Allografts for Treatment of End Stage Liver Disease Due to Hepatitis B Infection

Terminated· Merck & Co. logo

Merck & Co.·Phase 2·NCT00228592

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for HepeX-B. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — HepeX-B compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for HepeX-B. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Merck & Co. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Merck & Co.

HepeX-B

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

End Stage Liver Disease1 trial

References

Drug Info

Quick Facts

Related News